ALVOAnother cash cushion
Alvotech is back in the financing aisle, this time amending its existing credit agreement to unlock a term loan facility of up to $75 million. Translation: the company just gave itself a bigger liquidity lifeboat.
For a biotech, that matters a lot. These businesses can burn through cash while they’re building out manufacturing, pushing biosimilars forward, and generally trying to survive the long march from pipeline promise to real-world revenue.
Why investors are watching
On the one hand, this is a helpful move if you were worried about runway. More capital means more flexibility, less immediate pressure, and a little more room to keep the lights on without scrambling.
On the other hand, debt is still debt. So while this doesn’t scream distress, it does tell you the company wants extra financial firepower — and lenders aren’t handing out snacks; they’re expecting a payback.
Big picture
This comes just two weeks after Alvotech’s $165 million ordinary-shares fundraising, which makes the message pretty clear: management is shoring up liquidity from every angle it can. That can be reassuring if you like stability, but it also means the capital stack is getting busier by the minute.